By Bachem AG
To get in touch with Bachem brings new small molecule and generic peptide API offers to CPhI Japan, simply fill out the form below.
Subscribe to Supplier
Bachem brings new small molecule and generic peptide API offers to CPhI Japan
Important Information: The event, which was due to take place from 16th – 18th March 2020, has been postponed.
Bubendorf, Switzerland: –Peptide technology specialist Bachem AG is again be a prominent presence at Asia’s premier pharma trade expo, CPhI Japan in Tokyo.
Under its ‘Pioneering Partner for Peptides’ banner, the Bachem stand at Booth 1H-20 at Hall One of Tokyo’s Big Sight Exhibition Center will showcase its ever-expanding portfolio of CMO capabilities in peptide-based active pharmaceutical ingredients (APIs) and innovative selective glycosylation processes.
Small molecule and generic peptide APIs
For 2020, the Bachem display will focus on its innovative range of small molecule and generic peptide APIs and proprietary processes that harness its outstanding knowledge of peptide and carbohydrate chemistry, summed up in the Bachem.
The Bachem team in Tokyo will include Dr. Satoshi Mashiko, Head of Business Development, for Tokyo-based Bachem K.K. .
Expanding peptide market
Bachem has a close relationship with CPhI Japan, having attended the event every year since 2016.
It sees CPhI as a ‘must attend’ since peptides are a core part of its business and the Asian market, with Japan in particular, has become ever more important to the sector.
It will be reaching out to key suppliers and buyers for peptide generic APIs and small molecule generic APIs to present its advanced manufacturing cGMP multi-tonne capabilities in Switzerland and the USA, based on close to 50 Years’ experience in peptide chemistry.
Bachem will also feature its comprehensive Technical and Regulatory Support, with more than 50 DMF drug master files and CEP suitability certificates filed.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).
A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.
About CPhI Japan 2020
CPhI Japan is one of the family of high profile pharma trade shows created by UBM Live.
CPhI Japan 2020 is a three-day event opening March 16 at Tokyo’s Big Sight Exhibition Center. Apart from the main CPhI expo, there are six other zoned exhibitions: InnoPack for delivery systems and packing, P-MEC (including LabWorld) for machinery and equipment, ICSE for outsourcing solutions, bioLIVE for biopharma developments, FDF for finished dosage products, NEX for natural extracts.
In addition, CPHI Japan 2020 will feature the Pharma IT & Digital Expo.
This year’s CPhI Japan show is expected to exceed previous attendance records, attracting more than 20,000 visitors from 65 countries, along with more than 550 exhibitors.
The event is organized by Informa and UBM Japan with further information at: